Latest & greatest articles for opioid

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on opioid or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on opioid and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for opioid

1. Transmuscular quadratus lumborum block reduces opioid consumption and prolongs time to first opioid demand after laparoscopic nephrectomy

Transmuscular quadratus lumborum block reduces opioid consumption and prolongs time to first opioid demand after laparoscopic nephrectomy Transmuscular quadratus lumborum block reduces opioid consumption and prolongs time to first opioid demand after laparoscopic nephrectomy - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 (...) : 10.1136/rapm-2020-101745. Epub 2020 Oct 26. Transmuscular quadratus lumborum block reduces opioid consumption and prolongs time to first opioid demand after laparoscopic nephrectomy , , , , , , , , Affiliations Expand Affiliations 1 Department of Anaesthesiology, Zealand University Hospital, Roskilde, Denmark. 2 Department of Urology, Zealand University Hospital, Roskilde, Denmark. 3 Nørresundby, Denmark. 4 Anaesthesiology, Norfolk and Norwich University Hospital NHS Trust, Norwich, Norfolk, UK. 5

2021 EvidenceUpdates

2. Digital Health Technologies as an Adjunct to Medication Assisted Therapy for Opioid Use Disorder: Final Policy Recommendations

Digital Health Technologies as an Adjunct to Medication Assisted Therapy for Opioid Use Disorder: Final Policy Recommendations ©Institute for Clinical and Economic Review, 2020 Page 1 Digital Health Technologies as an Adjunct to Medication Assisted Therapy for Opioid Use Disorder: Final Policy Recommendations December 11, 2020 ©Institute for Clinical and Economic Review, 2020 Page 2 Policy Recommendations Introduction The following policy recommendations reflect main themes in the report (...) and those discussed during the Policy Roundtable discussion at the November 18, 2020 Midwest CEPAC public meeting on the use of digital health technologies (DHTs) as an adjunct to medication assisted treatment for opioid use disorder. At the meeting, ICER presented the findings of its revised report on these treatments and the Midwest CEPAC voting council deliberated on key questions related to their comparative clinical effectiveness, potential other benefits and contextual considerations, and long

2020 California Technology Assessment Forum

3. Benefits and Harms of Long-term Opioid Dose Reduction or Discontinuation in Patients with Chronic Pain: a Rapid Review

Benefits and Harms of Long-term Opioid Dose Reduction or Discontinuation in Patients with Chronic Pain: a Rapid Review Benefits and Harms of Long-term Opioid Dose Reduction or Discontinuation in Patients with Chronic Pain: a Rapid Review - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving (...) . Benefits and Harms of Long-term Opioid Dose Reduction or Discontinuation in Patients with Chronic Pain: a Rapid Review , , , , Affiliations Expand Affiliations 1 Evidence Synthesis Program (ESP) Coordinating Center, VA Portland Health Care System, R&D 71 3710 SW U.S. Veterans Hospital Road, Portland, OR, USA. katherine.mackey@va.gov. 2 Evidence Synthesis Program (ESP) Coordinating Center, VA Portland Health Care System, R&D 71 3710 SW U.S. Veterans Hospital Road, Portland, OR, USA. PMID: 33145689 DOI

2020 EvidenceUpdates

4. Comparison of Pupillometry With Surgical Pleth Index Monitoring on Perioperative Opioid Consumption and Nociception During Propofol-Remifentanil Anesthesia: A Prospective Randomized Controlled Trial

Comparison of Pupillometry With Surgical Pleth Index Monitoring on Perioperative Opioid Consumption and Nociception During Propofol-Remifentanil Anesthesia: A Prospective Randomized Controlled Trial Comparison of Pupillometry With Surgical Pleth Index Monitoring on Perioperative Opioid Consumption and Nociception During Propofol-Remifentanil Anesthesia: A Prospective Randomized Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage (...) Display options Format Share Permalink Copy Page navigation Randomized Controlled Trial Anesth Analg Actions . 2020 Nov;131(5):1589-1598. doi: 10.1213/ANE.0000000000004958. Comparison of Pupillometry With Surgical Pleth Index Monitoring on Perioperative Opioid Consumption and Nociception During Propofol-Remifentanil Anesthesia: A Prospective Randomized Controlled Trial , , , , , Affiliations Expand Affiliations 1 From the Department of Anesthesiology and Pain Medicine, Daegu Catholic University

2020 EvidenceUpdates

5. Opioids: risk of dependence and addiction

Opioids: risk of dependence and addiction Opioids: risk of dependence and addiction - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Show or hide search Search on GOV.UK Search National restrictions in England from 5 November Take action now for new rules in 2021 Opioids: risk of dependence (...) and addiction New recommendations following a review of the risks of dependence and addiction associated with prolonged use of opioid medicines (opioids) for non-cancer pain. Before prescribing opioids, discuss with the patient the risks and features of tolerance, dependence, and addiction, and agree together a treatment strategy and plan for end of treatment. Published 23 September 2020 From: Therapeutic area: Contents Advice for healthcare professionals: opioid medicines (opioids) provide relief from

2020 MHRA Drug Safety Update

6. Transdermal fentanyl patches for non-cancer pain: do not use in opioid-naive patients

Transdermal fentanyl patches for non-cancer pain: do not use in opioid-naive patients Transdermal fentanyl patches for non-cancer pain: do not use in opioid-naive patients - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Show or hide search Search on GOV.UK Search National restrictions (...) in England from 5 November Take action now for new rules in 2021 Transdermal fentanyl patches for non-cancer pain: do not use in opioid-naive patients Following a review of the risks associated with use of opioid medicines for non-cancer pain, the Commission on Human Medicines (CHM) has recommended that fentanyl transdermal patches are contraindicated in opioid-naive patients in the UK. Published 23 September 2020 From: Therapeutic area: Contents Advice for healthcare professionals: fentanyl is a potent

2020 MHRA Drug Safety Update

7. Prevention, Diagnosis, and Management of Opioids, Opioid Misuse, and Opioid Use Disorder in Older Adults

Prevention, Diagnosis, and Management of Opioids, Opioid Misuse, and Opioid Use Disorder in Older Adults Prevention, Diagnosis, and Management of Opioids, Opioid Misuse, and Opioid Use Disorder in Older Adults Technical Brief Number 37 RTechnical Brief Number 37 Prevention, Diagnosis, and Management of Opioids, Opioid Misuse, and Opioid Use Disorder in Older Adults Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville (...) acknowledgment and citation of its work. Suggested language for acknowledgment: This work was based on an evidence report, Prevention, Diagnosis, and Management of Opioids, Opioid Misuse, and Opioid Use Disorder in Older Adults, by the Evidence-based Practice Center Program at the Agency for Healthcare Research and Quality (AHRQ). Suggested citation: Zullo AR, Danko KJ, Moyo P, Adam GP, Riester M, Kimmel HJ, Panagiotou OA, Beaudoin FL, Carr D, Balk EM. Prevention, Diagnosis, and Management of Opioids, Opioid

2020 Effective Health Care Program (AHRQ)

8. Naldemedine (opioid-induced constipation) - Benefit assessment according to §35a Social Code Book V

Naldemedine (opioid-induced constipation) - Benefit assessment according to §35a Social Code Book V 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Naldemin (opioidinduzierte Obstipation) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 13 August 2020). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally (...) binding. Extract IQWiG Reports – Commission No. A20-45 Naldemedine (opioid-induced constipation) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A20-45 Version 1.0 Naldemedine (opioid-induced constipation) 13 August 2020 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher Institute for Quality and Efficiency in Health Care Topic Naldemedine (opioid-induced constipation) – Benefit assessment according to §35a Social

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

9. Bilateral ultrasound-guided thoracic erector spinae plane blocks using a programmed intermittent bolus improve opioid-sparing postoperative analgesia in pediatric patients after open cardiac surgery: a randomized, double-blind, placebo-controlled trial

Bilateral ultrasound-guided thoracic erector spinae plane blocks using a programmed intermittent bolus improve opioid-sparing postoperative analgesia in pediatric patients after open cardiac surgery: a randomized, double-blind, placebo-controlled trial Bilateral ultrasound-guided thoracic erector spinae plane blocks using a programmed intermittent bolus improve opioid-sparing postoperative analgesia in pediatric patients after open cardiac surgery: a randomized, double-blind, placebo-controlled (...) displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Reg Anesth Pain Med Actions . 2020 Oct;45(10):805-812. doi: 10.1136/rapm-2020-101496. Epub 2020 Aug 19. Bilateral ultrasound-guided thoracic erector spinae plane blocks using a programmed intermittent bolus improve opioid-sparing postoperative analgesia in pediatric patients after open cardiac surgery: a randomized, double-blind, placebo-controlled trial

2020 EvidenceUpdates

10. Naldemedine for treating opioid-induced constipation

Naldemedine for treating opioid-induced constipation Naldemedine for treating opioid-induced constipation T echnology appraisal guidance Published: 30 September 2020 www.nice.org.uk/guidance/ta651 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Your responsibility Your responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When (...) sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Naldemedine for treating opioid-induced constipation (TA651) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 19Contents Contents 1 Recommendations 4 2 Information about naldemedine 5 Marketing authorisation indication 5 Dosage in the marketing authorisation 5 Price 5 3

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

11. Key Evidence Supporting Prescription Opioids Approved by the U.S. Food and Drug Administration, 1997 to 2018. (Abstract)

Key Evidence Supporting Prescription Opioids Approved by the U.S. Food and Drug Administration, 1997 to 2018. Little is known about the evidence required by the U.S. Food and Drug Administration (FDA) for new approvals of opioid analgesics.To characterize the quality of safety and efficacy data in new drug applications (NDAs) for opioid analgesics approved by the FDA between 1997 and 2018.Cross-sectional analysis.Data from ClinicalTrials.gov, FDA reviews, and peer-reviewed publications.Patients (...) with pain who participated in phase 3 pivotal trials.FDA-approved opioid analgesics.Key characteristics of each NDA, including the number, size, and duration of pivotal trials; trial control groups; the use of enriched trial populations; and systematically measured safety outcomes.Most of the 48 NDAs evaluated were for new dosage forms (n = 25 [52.1%]) or new formulations (n = 9 [18.8%]); only 1 (2.1%) was for a new molecular entity. Of 39 NDAs approved for treating chronic pain, only 21 products were

2020 Annals of Internal Medicine

12. National Practice Guideline For the Treatment of Opioid Use Disorder

types of public sector clinics that can be authorized to prescribe the partial opioid agonist buprenorphine in outpatient settings. There is no regulation, per se, of the clinic site itself, but of the individual clinician who prescribes buprenorphine. Opiate: One of a group of alkaloids derived from the opium poppy(Papaversomniferum), with the ability to induce analgesia, euphoria, and, in higher doses, stupor, coma, and respiratory depression. The term excludes synthetic opioids. Opioid: A current (...) term for any psychoactive chemical that resembles morphine in pharmacological effects, includ- ing opiates and synthetic/semisynthetic agents that exert their effects by binding to highly selective receptors in the brain where morphine and endogenous opioids affect their actions. Opioid agonist medication: Opioid agonist medica- tions pharmacologically occupy and activate opioid receptors in the body. They thereby relieve withdrawal symptoms and reduce or extinguish cravings for opioids. Opioid

2020 American Society of Addiction Medicine

13. Emergency Department-initiated Interventions for Patients With Opioid Use Disorder: A Systematic Review

Emergency Department-initiated Interventions for Patients With Opioid Use Disorder: A Systematic Review Emergency Department-initiated Interventions for Patients With Opioid Use Disorder: A Systematic Review - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest public (...) at most: Send even when there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Acad Emerg Med Actions . 2020 Jun 17. doi: 10.1111/acem.14054. Online ahead of print. Emergency Department-initiated Interventions for Patients With Opioid Use

2020 EvidenceUpdates

14. The Efficacy and Safety of Opioids in Total Joint Arthroplasty: A Direct Meta-Analysis

The Efficacy and Safety of Opioids in Total Joint Arthroplasty: A Direct Meta-Analysis The Efficacy and Safety of Opioids in Total Joint Arthroplasty: Systematic Review and Direct Meta-Analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest public health (...) at most: Send even when there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation J Arthroplasty Actions . 2020 May 27;S0883-5403(20)30572-6. doi: 10.1016/j.arth.2020.05.032. Online ahead of print. The Efficacy and Safety of Opioids in Total

2020 EvidenceUpdates

15. Predictors of Prolonged Opioid Use After Initial Prescription for Acute Musculoskeletal Injuries in Adults : A Systematic Review and Meta-analysis of Observational Studies. (Abstract)

Predictors of Prolonged Opioid Use After Initial Prescription for Acute Musculoskeletal Injuries in Adults : A Systematic Review and Meta-analysis of Observational Studies. Opioids are frequently prescribed for acute musculoskeletal injuries and may result in long-term use and consequent harms.To explore factors associated with persistent opioid use after its prescription for acute musculoskeletal injury.Searches of multiple electronic databases, without language restrictions, from inception (...) to 6 January 2020, and reference lists of selected articles.Observational studies of adults with opioid prescriptions for outpatient acute musculoskeletal injuries, in an adjusted model, that explored risk factors for prolonged use.6 reviewers, working in pairs, independently extracted data, rated the quality of studies, and evaluated the certainty of evidence.14 cohorts with 13 263 393 participants were included. The overall prevalence of prolonged opioid use after musculoskeletal injury for high

2020 Annals of Internal Medicine

16. Retention Strategies for Medications for Addiction Treatment in Adults With Opioid Use Disorder

Retention Strategies for Medications for Addiction Treatment in Adults With Opioid Use Disorder Retention Strategies for Medications for Addiction Treatment in Adults With Opioid Use Disorder: A Rapid Evidence Review Rapid Evidence Product RRapid Evidence Product Retention Strategies for Medications for Addiction Treatment in Adults With Opioid Use Disorder: A Rapid Evidence Review Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers (...) , Gilbert J, Hilgart J, Fiordalisi C, Hubbard K, Brandt I, Stoeger E, Paynter R, Korthuis PT, Guise J-M. Retention Strategies for Medications for Addiction Treatment in Adults With Opioid Use Disorder: A Rapid Evidence Review. (Prepared by the Scientific Resource Center under Contract No. HHSA 290-2017- 00003C). AHRQ Publication No. 20-EHC012. Rockville, MD: Agency for Healthcare Research and Quality. July 2020. Posted final reports are located on the Effective Health Care Program search page. DOI

2020 Effective Health Care Program (AHRQ)

17. HTX-011 Reduced Pain and Opioid Use After Primary Total Knee Arthroplasty: Results of a Randomized Phase 2b Trial Full Text available with Trip Pro

HTX-011 Reduced Pain and Opioid Use After Primary Total Knee Arthroplasty: Results of a Randomized Phase 2b Trial HTX-011 Reduced Pain and Opioid Use After Primary Total Knee Arthroplasty: Results of a Randomized Phase 2b Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get (...) there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation J Arthroplasty Actions . 2020 May 27;S0883-5403(20)30584-2. doi: 10.1016/j.arth.2020.05.044. Online ahead of print. HTX-011 Reduced Pain and Opioid Use After Primary Total Knee Arthroplasty: Results of a Randomized Phase 2b Trial

2020 EvidenceUpdates

18. Critical Issues in the Prescribing of Opioids for Adult Patients in the Emergency Department

Critical Issues in the Prescribing of Opioids for Adult Patients in the Emergency Department ACEP // Opioids Popular Recommendations PEER ultrasound LLSA sepsis Log In Log In Topics Practice Education Advocacy About ACEP Topics TOPICS Quick Access Current News Practice Administration Life as a Physician Patient Care By Medical Focus Education In Education Upcoming Conferences Earn CME Now Featured Publication Advocacy Federal Advocacy State Advocacy Get Involved Groups to Join About ACEP Who We (...) Are How We Serve What We Believe Membership FEATURED BENEFIT Popular Recommendations PEER ultrasound LLSA sepsis QUICK ACCESS CURRENT NEWS TOPICS BY MEDICAL FOCUS ADMINISTRATION LIFE AS A PHYSICIAN PATIENT CARE UPCOMING CONFERENCES EARN CME NOW FEATURED PUBLICATION IN EDUCATION GROUPS TO JOIN FEDERAL ADVOCACY STATE ADVOCACY GET INVOLVED MEMBERSHIP FEATURED BENEFIT WHO WE ARE HOW WE SERVE WHAT WE BELIEVE / / Opioids Opioids (Jun 2020) Critical Issues in the Prescribing of Opioids for Adult Patients

2020 American College of Emergency Physicians

19. Efficacy and Safety of Peripherally Acting Mu-Opioid Receptor Antagonists for the Treatment of Opioid-Induced Constipation: A Bayesian Network Meta-analysis

Efficacy and Safety of Peripherally Acting Mu-Opioid Receptor Antagonists for the Treatment of Opioid-Induced Constipation: A Bayesian Network Meta-analysis Efficacy and Safety of Peripherally Acting Mu-Opioid Receptor Antagonists for the Treatment of Opioid-Induced Constipation: A Bayesian Network Meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features (...) Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Pain Med Actions . 2020 Jun 3;pnaa152. doi: 10.1093/pm/pnaa152. Online ahead of print. Efficacy and Safety of Peripherally Acting Mu-Opioid Receptor Antagonists for the Treatment of Opioid-Induced Constipation: A Bayesian Network Meta-analysis , , , , Affiliations Expand Affiliations 1 Department of Gastroenterology, The Second Affiliated

2020 EvidenceUpdates

20. New directions in the treatment of opioid withdrawal. Full Text available with Trip Pro

New directions in the treatment of opioid withdrawal. The treatment of opioid withdrawal is an important area of clinical concern when treating patients with chronic, non-cancer pain, patients with active opioid use disorder, and patients receiving medication for opioid use disorder. Current standards of care for medically supervised withdrawal include treatment with μ-opioid receptor agonists, (eg, methadone), partial agonists (eg, buprenorphine), and α2-adrenergic receptor agonists (eg (...) , clonidine and lofexidine). Newer agents likewise exploit these pharmacological mechanisms, including tramadol (μ-opioid receptor agonism) and tizanidine (α2 agonism). Areas for future research include managing withdrawal in the context of stabilising patients with opioid use disorder to extended-release naltrexone, transitioning patients with opioid use disorder from methadone to buprenorphine, and tapering opioids in patients with chronic, non-cancer pain.Copyright © 2020 Elsevier Ltd. All rights

2020 Lancet